دورية أكاديمية
أعرض في EDS

Relation of STAT3 rs1053005 Variation and miR-452-3p with Osteoarthritis Susceptibility and Severity and the Clinical Response to High-Molecular-Weight Hyaluronic Acid Injection in Osteoarthritis Patients.

التفاصيل البيبلوغرافية
العنوان: Relation of STAT3 rs1053005 Variation and miR-452-3p with Osteoarthritis Susceptibility and Severity and the Clinical Response to High-Molecular-Weight Hyaluronic Acid Injection in Osteoarthritis Patients.
المؤلفون: Wahba AS; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Mohamed DA; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Mehanna MT; Department of Orthopedic Surgery and Trauma, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt., Mesbah NM; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Abo-Elmatty DM; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Mehanna ET; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.
المصدر: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2023 Nov 27; Vol. 13 (23). Date of Electronic Publication: 2023 Nov 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101658402 Publication Model: Electronic Cited Medium: Print ISSN: 2075-4418 (Print) Linking ISSN: 20754418 NLM ISO Abbreviation: Diagnostics (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2011]-
مستخلص: Polymorphisms in the 3' untranslated region of STAT3 mRNA can derange STAT3 gene expression via modifying the microRNA-binding site. This study aimed to examine the impact of STAT3 rs1053005 variation and miR-452-3p expression on osteoarthritis (OA) susceptibility and severity and the efficacy of intra-articular high-molecular-weight hyaluronic acid (HMW-HA) injection as a therapy option for knee OA. Two hundred and fifty-eight OA patients and 200 healthy controls were enrolled in the study. STAT3 genotyping and STAT3 and miR-452-3p expression were carried out using allelic-discrimination PCR and quantitative real-time PCR. Functional assessment and pain evaluation were performed for all patients. Eighty-three patients received HMW-HA injections, and multiple follow-up visits were performed. STAT3 mRNA was upregulated, and expression was positively associated with plasmin, TNF-α, MMP-3, and STAT3 serum levels, whereas miR-452-3p was downregulated and negatively associated with the previously mentioned parameters in OA patients. Osteoarthritis patients had a lower prevalence of the minor allele of the rs1053005 variant ( p < 0.001). Plasmin, TNF, MMP-3, and STAT3 mRNA and protein levels were significantly decreased, and miR-452-3p expression was significantly increased in the GG genotype compared to AG and AA genotypes. HMW-HA injection improved OA patients' clinical scores with concomitant decreased STAT3 levels and enhanced expression of miR-452-3p. More efficient improvement was observed in rs1053005 AG + GG genotype carriers vs. AA genotype carriers. The G allele of STAT3 rs1053005 (A/G) polymorphism was associated with decreased OA susceptibility and severity and enhanced clinical response to HMW-HA injection, possibly via enhancing miR-452-3p binding and a subsequent decrease in STAT3 expression.
References: Front Pharmacol. 2022 Apr 25;13:897539. (PMID: 35548357)
RMD Open. 2018 Oct 11;4(2):e000734. (PMID: 30402266)
Nat Rev Rheumatol. 2022 May;18(5):258-275. (PMID: 35165404)
Biomed Pharmacother. 2017 Dec;96:1209-1215. (PMID: 29174854)
Prog Mol Biol Transl Sci. 2017;148:305-325. (PMID: 28662824)
Int J Biol Sci. 2020 Jan 30;16(6):970-980. (PMID: 32140066)
Osteoarthritis Cartilage. 2018 Mar;26(3):319-325. (PMID: 29229563)
Osteoarthritis Cartilage. 2009 Apr;17(4):464-72. (PMID: 19008124)
BMC Med Genet. 2018 Apr 2;19(1):52. (PMID: 29609539)
Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):837-842. (PMID: 32016989)
Osteoarthritis Cartilage. 2013 Sep;21(9):1145-53. (PMID: 23973124)
Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. (PMID: 24462672)
Front Immunol. 2022 Jul 19;13:902652. (PMID: 35928809)
Diabetol Metab Syndr. 2022 Jan 6;14(1):4. (PMID: 34991691)
Int J Mol Sci. 2022 Nov 08;23(22):. (PMID: 36430200)
J Clin Med. 2021 Jul 19;10(14):. (PMID: 34300344)
Int J Mol Sci. 2021 Aug 26;22(17):. (PMID: 34502117)
Bone Res. 2017 Jan 17;5:16044. (PMID: 28149655)
Life (Basel). 2022 Apr 14;12(4):. (PMID: 35455072)
Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S28-33. (PMID: 26806183)
J Rheumatol. 1990 Aug;17(8):1022-4. (PMID: 2213777)
Cell Commun Signal. 2023 Apr 3;21(1):67. (PMID: 37013568)
Saudi J Biol Sci. 2018 May;25(4):672-679. (PMID: 29736142)
Int J Mol Sci. 2023 Feb 14;24(4):. (PMID: 36835197)
Cancer Gene Ther. 2020 Nov;27(10-11):739-753. (PMID: 32203060)
Inflamm Res. 2021 Aug;70(8):903-914. (PMID: 34283251)
Indian J Psychol Med. 2013 Apr;35(2):121-6. (PMID: 24049221)
BMJ. 2022 Jul 6;378:e069722. (PMID: 36333100)
Osteoarthritis Cartilage. 2009 Aug;17(8):971-9. (PMID: 19303469)
Front Immunol. 2022 Jul 04;13:907750. (PMID: 35860250)
Arthritis Res Ther. 2015 Nov 07;17:314. (PMID: 26546411)
Exp Ther Med. 2018 Dec;16(6):4737-4744. (PMID: 30542428)
J Orthop Sports Phys Ther. 1998 Aug;28(2):88-96. (PMID: 9699158)
J Rheumatol. 1991 Dec;18(12):1863-71. (PMID: 1724464)
Biomed Pharmacother. 2019 Jan;109:2464-2471. (PMID: 30551507)
Clin Cases Miner Bone Metab. 2015 Jan-Apr;12(1):31-3. (PMID: 26136793)
Arthritis Res Ther. 2017 Feb 2;19(1):18. (PMID: 28148295)
Clin Cases Miner Bone Metab. 2016 May-Aug;13(2):131-134. (PMID: 27920810)
Clin Orthop Relat Res. 2016 Aug;474(8):1886-93. (PMID: 26872913)
Clin Transl Oncol. 2023 May;25(5):1189-1206. (PMID: 36622551)
J Cell Physiol. 2017 Nov;232(11):2957-2963. (PMID: 28425564)
Arthritis Care Res (Hoboken). 2017 Sep;69(9):1287-1296. (PMID: 28118523)
Lupus. 2022 Mar;31(3):338-346. (PMID: 35073195)
Exp Mol Med. 2020 Mar;52(3):367-379. (PMID: 32152451)
Cytokine Growth Factor Rev. 2018 Dec;44:38-50. (PMID: 30340925)
Ann Rheum Dis. 1997 Sep;56(9):550-7. (PMID: 9370880)
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2021 Jun 20;39(6):412-417. (PMID: 34218555)
BMC Musculoskelet Disord. 2019 May 7;20(1):196. (PMID: 31064359)
JAKSTAT. 2012 Jul 1;1(3):143-50. (PMID: 24058763)
Biomedicines. 2023 Jan 21;11(2):. (PMID: 36830841)
J Bone Miner Res. 2005 Jan;20(1):30-40. (PMID: 15619667)
Orthop Surg. 2021 Jul;13(5):1662-1672. (PMID: 34105258)
Bone Joint Res. 2020 Oct 16;9(10):675-688. (PMID: 33101657)
فهرسة مساهمة: Keywords: HMW-HA injections; STAT3; miR-452-3p; osteoarthritis; rs1053005
تواريخ الأحداث: Date Created: 20231209 Latest Revision: 20231209
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC10706565
DOI: 10.3390/diagnostics13233544
PMID: 38066785
قاعدة البيانات: MEDLINE
الوصف
تدمد:2075-4418
DOI:10.3390/diagnostics13233544